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Abstract
Background: TCF7L2 rs7903146 is an important genetic factor predicting type 2 diabetes (T2DM) which has also been linked
to higher cardiovascular risk. To date, there is little information about the additional impact of this single nucleotide
polymorphism (SNP) beyond glucose metabolism.
Methodology/Principal Findings: We studied whether rs7903146 influenced postprandial lipid metabolism in three
different populations (healthy young men, metabolic syndrome (MetS) patients and elderly persons). Eighty-eight healthy
males were submitted to a single saturated fatty acid-rich test meal. Additionally, 110 middle-aged MetS patients and 20
healthy elderly persons ($65 years) were submitted to three different dietary models followed by test meals. Minor allele
homozygotes for rs7903146 showed a worse postprandial lipemia profile in young males, as seen by a lower HDL-
cholesterol and Apo A1 concentration during the postprandial lipemia and a trend towards higher triglycerides (TG), than
the other genotypes. In healthy elderly persons, carriers of the minor allele showed higher total cholesterol, LDL-cholesterol,
Apo B and TG in the fasting state, and a higher postprandial area under the curve for total cholesterol, Apo B, small-
triglyceride rich lipoprotein (TRL) cholesterol and small-(TRL) triglycerides. These results were accompanied by differential
changes in adipokines. We did not observe any influence of rs7903146 on the postprandium of MetS patients.
Conclusions/Significance: Healthy young males and elderly persons who are carriers of the mutant allele for rs7903146
have an impaired postprandial lipid metabolism that may be mediated by an alteration in adipokine regulation, and may be
related to the higher cardiovascular risk observed in these persons.
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Introduction
Postprandial lipemia is characterized as a period by an increase
in proinflammatory and prooxidant species in the bloodstream,
along with a transient increase in some lipid fractions with direct
pro-atherogenic properties, such as small triglyceride-rich lipo-
proteins (TRL). Several studies have linked the extent of this state
to the development of coronary heart disease [1–3]. How long the
state lasts varies widely among healthy individuals, and both
intrinsic and extrinsic factors have been identified, with genetic
background and diet those factors which have been most
extensively studied [4–10]. Several diseases have also been
recognized as powerful modifiers of postprandial lipemia, such
as type 2 diabetes (T2DM), and metabolic syndrome (MetS).
These two conditions present an altered lipid metabolism, with
increased triglyceride levels and increased postprandial lipemia,
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along with lower HDL levels and a proatherogenic LDL
phenotype consisting of smaller and denser molecules. The
combination of all these features makes up what is called
atherogenic (or diabetic) dyslipidemia [11–12].
Variations at the TCF7L2 (a subgroup of T-cell-specific
transcription factors) locus have been identified as the most
important genetic predictors of T2DM in Genome-wide associa-
tion studies [13–15]. TCF7L2 are transcriptor factors, main
effectors of the Wnt ligand family, which have been involved in the
differentiation of adipocytes, the regulation of adipokines and
pancreatic beta-cell function, among others [16].
We recently reported how a variation of the rs7903146 gene is
linked to a dysfunction in glucose metabolism during the
postprandial state in MetS patients, without affecting fasting
glucose or insulin, and mainly influencing markers of beta-cell
function, such as those associated to insulin secretion [17].
In contrast to the currently burgeoning data on the influence of
TCF7L2 variations on glucose metabolism, which is the subject of
over 80 studies, their influence on postprandial lipids is at present
unexplored, with only one study reporting an altered postprandial
lipid profile in consumers of high polyunsaturated fatty acids
(PUFA) [18]. Furthermore, neither the effects on different
populations nor their possible underlying mechanisms (beyond
the beta-cell function) have been explored, despite the well-known
regulation of adipocyte differentiation by TCF7L2.
In this study, we aimed to explore the influence of rs7903146 on
postprandial lipid metabolism in different populations and under
different dietary models, and relate our findings to possible
underlying mechanisms, by assessing both beta-cell function and
the regulation of adipokines.
With this aim, we first conducted a closely-controlled interven-
tion study of a group of young men, to assess the effect of the SNPs
on postprandial lipemia in a healthy cohort, where modification
due to beta-cell dysfunction was unlikely, and which has been
identified as a good model to test for new gene variations affecting
postprandial lipemia [6–10,19]. Then, to corroborate our findings,
we explored the effects of the SNP on two other populations: one
with MetS and another made up of healthy elderly persons.
Methods
Ethics
In the three studies (young men, MetS and healthy elderly
persons), all participants signed an informed consent agreement.
The experimental protocols were approved by the local ethics
committees at the Bioethical Committee of the Jagiellonian
University, Medical College Krakow, Poland and the Comite´
E´tico de Investigacio´n Clı´nica, Hospital Universitario Reina Sofı´a,
Cordoba, Spain, according to the Helsinki Declaration of 1975
(revised in 1983).
Young Male Population and Fat-loading Test
Eighty-eight healthy male students at the University of Cordoba
were recruited for the study. They had a mean 6SD age of
2364 y. Other studies reporting exhaustive baseline characteris-
tics of this population have been published elsewhere [7,9–10,19–
20]. Briefly described, participants were free of any known
condition when recruited for the study, and were not taking any
medication. They had plasma total cholesterol concentrations
,240 mg/dL, plasma triacylglycerol concentrations ,150 mg/
dL, and BMI,30 kg/m2. The metabolic study was carried out in
the Research Unit of the Reina Sofia University Hospital. After a
12-h fast, volunteers were given a fatty meal. The amount of fat
given, per kg body wt, was 1 g fat and 7 mg cholesterol. The meal
contained 65% of energy as fat, 10% of energy as protein, and
25% of energy as carbohydrates; it was consumed in 20 min. After
this meal, subjects fasted for 11 h, but they were allowed to drink
water. Blood samples were drawn before the meal, every hour
until hour 6, and every 2.5 h until hour 11. Extensive method-
ology has been published [7].
MetS Population and Fat-loading Test
This study was carried out within the LIPGENE study. A total
of 117 patients with MetS from the Lipid and Atherosclerosis Unit
at the IMIBIC/Reina Sofia University Hospital, Spain, and the
Department of Clinical Biochemistry, Jagiellonian University
School of Medicine, Poland, participated in this sub-study [21–
22].
Patients were randomly stratified to 1 of 4 dietary interventions
for 12 wk, as published [21–22]. In brief, there were four
isoenergetic diets which differed in fat quantity and quality. Two
diets were designed to provide 38% energy (E) from fat: a high-fat,
saturated fatty acids-rich diet (HSFA), which was designed to
provide ,16% E as SFA, and a a high-fat, monounsaturated fatty
acids-rich diet (HMUFA) diet designed to provide ,20% E from
MUFA. The other 2 diets were low fat, high carbohydrates
(LFHCC) diets (LFHCC and LFHCC (n-3); 28% E from fat); the
LFHCC (n-3) diet included a 1.24-g/d supplement of long chain
(n-3) PUFA [ratio of 1.4 eicosapentaenoic acid (EPA):1 docosa-
hexaenoic acid (DHA)] in form of capsules and the LFHCC diet
included a 1.24-g/d supplement of control high-oleic sunflower
seed oil capsules (placebo). The fat-loading test was performed pre-
and post-intervention, providing the same amount of fat (0.7 g/kg
body weight), the fat composition of which reflected the amount
consumed within the intervention period. Blood samples were
taken at 0,2,4,6 and 8 hours after intake. Test meals provided an
equal amount of fat (0.7 g/kg body weight), energy content
(40.2 kJ/kg body weight) and cholesterol (5 mg/kg of body
weight). The test meal provided 65% of E as fat, 10% as protein,
and 25% as carbohydrates. During the postprandial assessment,
the participants rested and did not consume any other food for
9 h, but were allowed to drink water. The composition of the test
meals was as follows: HSFA, 38% E from SFA; HMUFA, 43% E
from MUFA; LFHCC with placebo capsules, 16% E as PUFA;
LFHCC with long chain (n-3) PUFA, 16% E as PUFA [1.24 g/d
of long chain (n-3) PUFA (ratio 1.4 EPA:1 DHA)].
Elderly Population and Fat-loading Test
Twenty elderly ($65 years) persons, 10 men and 10 women,
entered the study. They had total cholesterol concentration equal
to or ,250 mg/dl, and were non-smokers. The clinical exclusion
criteria were age,65 years, diabetes or other endocrine disorders,
chronic inflammatory conditions, kidney or liver dysfunction, iron
deficiency anemia (hemoglobin ,12 g/dL men, ,11 g/dL
women), prescribed hypolipidemic and anti-inflammatory medi-
cation, fatty acid supplements including fish oil, consumers of high
doses of antioxidant vitamins (A, C, E, b-carotene), highly-trained
or endurance athletes or those who participated in more than
three periods of intense exercise per week, weight change equal or
.3 kg within the last 3 months, smokers, and subjects with alcohol
or drug abuse (based on clinical judgment).
The participants were randomly assigned to receive, in a
crossover design, three isocaloric diets for a 4-week period each.
The three diets were as follows: (1) A Mediterranean diet
supplemented with coenzyme Q (Med+CoQ diet) (200 mg/day
in capsules), containing 15% of energy as protein, 47% of energy
as carbohydrate and 38% of total energy as fat [24% MUFA,
provided by virgin olive oil, 10% SFA, 4% PUFA]. (2) A
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Mediterranean diet not supplemented with CoQ (Med diet), with
the same composition of the first diet, but supplemented by
placebo capsules, and (3) A Western diet rich in SFA, with 15% of
energy as protein, 47% of energy as carbohydrate, and 38% of
total energy as fat (12% MUFA, 22% SFA, 4% PUFA). The
amount of fat given, per kg body wt, was 0.7 g fat and 5 mg
cholesterol. At the end of the dietary intervention period, the
subjects were given a fatty test meal with the same fat composition
as consumed in each of the diets. Subsequent blood samples were
taken at 0, 2 and 4 h. The meals contained 65% of energy as fat,
10% of energy as protein, and 25% of energy as carbohydrates,
were consumed in 20 min, and their fatty acid composition was as
follows: Med with CoQ (400 mg in capsules) test meal (12% SFA,
43% MUFA, 10% PUFA); Med with placebo capsule test meal
(12% SFA, 43% MUFA, 10% PUFA); and SFA-rich test meal
(38% SFA, 21% MUFA, 6% PUFA).
Laboratory Methods
Laboratory methodology has been published extensively for
the three populations elsewhere [7,23–24]. Beta-cell function
was explored by the HOMA-B method (360*fasting insulin in
mU/mL)/(fasting glucose in mg/dL-63)% [25]. Blood collection
and TRL (Large and Small) isolation were performed by
standard methodology, as previously published [7] (File S1).
Total cholesterol (Chol) and triglycerides (TG) in plasma and
lipoprotein fractions were assayed by enzymatic procedures.
Apo A1 and Apo B were determined by turbidimetry [26].
HDL-C was measured by the dextran sulfate-Mg2+ method, as
described [27]. LDL-C levels were estimated using the
Friedewald formula [28] for the healthy young men and the
MetS cohorts, and calculating the difference between the total
cholesterol before ultracentrifugation and that at the bottom
part of the tube after ultracentrifugation at a density of
1019 kg/L for the elderly persons cohort. Plasma concentrations
of adiponectin, leptin and resistin were measured by enzyme-
linked immunosorbent assay by the Milliplex MAP kit (Millipore
Corporation, Billerica, MA, USA) using a Bio-Plex 200 System
(BIORAD Laboratories Hercules, CA, USA).
Methodology for Choosing and Genotyping the TCF7L2
Gene Variant
We chose rs7903146 as a good candidate for studying the
phenotypical effects on lipids of TCF7L2 based on strong
indications in previous literature (more than 175 articles reporting
phenotypical associations), some of which suggested that its
functionality affected glucose metabolism [29–32]. Furthermore,
the only article reporting the postprandial triglyceride effects of
TCF7L2 involved rs7903146 [18]. Genotyping of the young male
cohort and the elderly persons cohort was performed by Progenika
inc. (Medford, MA 02155 USA). Genotyping of the MetS
population was performed by Illumina Inc., (San Diego, CA,
USA). The Hardy-Weinberg equilibrium (HWE) was tested by
Fishers exact test.
Statistical Analysis
The statistical analysis methods employed here are similar to
those which we have published previously with respect to the gene-
postprandial state interaction [9–10,19].
Analysis of lipid parameters and genotype.
The influence of the SNP on the size of the postprandial lipid
fractions was analyzed by univariate ANOVA for area under the
curve (AUC), defined as the area between the plasma concen-
tration-versus-time curve, using the trapezoidal rule, with the
SNP included as an independent factor, and BMI, center of
origin, gender, age and diet (if applicable) as covariates. When we
found significant data in the univariate ANOVA, we performed
repeated-measures ANOVA for both the overall gene influence
(global ANOVA, p for gene influence), the kinetics of the
response (p for time), and the interaction of both factors
(time*gene). We used the dominant genetic model as the default
model, based on previous data [17]. We also performed the
additive model in the young cohort, inferring that in such a
population a higher genetic challenge might be necessary to
produce phenotypic findings.
A p-value of less than 0.05 was considered significant. All data
presented in the text and tables are expressed as mean 6S.E,
unless otherwise specified. SPSS 19.0 for Windows (SPSS Inc.,
Chicago, IL, USA) was used for statistical comparisons.
Results
The baseline of the participants of the three cohorts is reported
in Table 1. In the cohort of elderly persons, total cholesterol, TG,
LDL and Apo B were higher in the fasting state in the carriers of
the rs7903146 than in the homozygotes for the major allele. We
did not find any other differences in baseline characteristics
between CC and CT/TT in either of the other two cohorts. The
minor allele frequencies in the young men, MetS and elderly
cohorts were 0.39, 0.31, and 0.32. All the frequencies were in the
Hardy-Weinberg equilibrium. As an internal control, we used
Bootstraping methods to confirm the main findings of this article.
Bootstrapping test used the following specifications: Simple
sampling method, 10,000 permutations per test and 95% of
confidence interval. C.I.95%: Difference of means. In all cases,
Boostrapping confirmed the results from ANOVA test. File S2
shows this information.
Young Male Population and Fat-loading Test
Table 2 shows the area under the curve (AUC) of the different
lipid fractions after the test meal. Homozygotes for the rare allele
(TT) of rs7903146 exhibited a lower AUC than the other two
genotypes for HDL (p = 0.028), and Apo A1 (p = 0.011). There
was also a trend towards lower total cholesterol AUC in TT,
although it did not reach statistical significance (p = 0.053).
When evaluating the timepoint effects (repeated measures), we
found differences for HDL at all measurements except at the 6th
hour (timepoints: 0, 1, 2, 3, 4, 5, 8.5 and 11 hours). Significance
for differences at 6th hour were p = 0.080 and p = 0.086 for TT vs
CC and CT respectively. For Apo A1, the results were similar,
with differences at all timepoints between TT and CT and at all
except timepoint 6 hours for TT vs CC (p = 0.142).
AUC of Adiponectin was higher, and leptin lower, in the
homozygotes for the major allele (all p,0.05), Figure 1. No
differences were found for HOMA-B index (p.0.05, data not
shown).
MetS Population and Fat-loading Test
We did not find any significant differences in the different lipid
particles analyzed, depending on the rs7903146 genotype. There
were non-significant higher means for TG, large-TRL TG, and
lower means for Apo A1 in the carriers of the mutant allele
(Table 3). HOMA-B index was analyzed previously in a sample
that contained this cohort in a previous report, and a lower
HOMA-B index was observed in the carriers of the minor alleles
[17].
TCF7L2 SNPs Regulate Postprandial Lipids
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Elderly Population and Fat-loading Test
Table 4 summarizes the results of the test meal tests in the
elderly persons. Carriers of the minor allele for rs7903146 had a
higher AUC of total cholesterol (p = 0.028), small-TRL TG
(p = 0.018); small-TRL cholesterol (p = 0.015); Apo B (p = 0.042)
and small-TRL Apo B (p = 0.004) (Figure 2). The repeated
measures test revealed that the differences were evident at all
timepoints (fasting, 1st, 2nd and 4th hours) for total cholesterol (all
p,0.036), small-TRL TG (all p,0.042), small-TRL cholesterol
(all p,0.044) and small-TRL Apo B (all p,0.033) and at all
timepoints except 3rd hour for Apo B (all p,0.042 except
p = 0.070 at 3rd hour). The AUC of leptin was lower, and resistin
higher in the carriers of the minor allele for rs7903146. We did not
find any influence of rs7903146 in HOMA-B index.
Discussion
Our study shows that carriers of the rare allele of TCF7L2
rs7903146 have a disrupted lipid metabolism, which is seen in
different ways depending on age and baseline conditions. Healthy
young men have a lower HDL and Apo A1 response to a saturated
fatty acid-rich meal, while healthy elderly persons show increased
postprandial lipemia, with higher totals of plasma cholesterol and
Apo B, and a higher accumulation of Apo B, cholesterol and
triglycerides in small TRL lipid particles.
Variations in TCF7L2 (particularly rs7903146) are a genetic risk
factor for T2DM [13–15,33–34]. The alterations caused by these
gene variations in the glucose metabolism of diabetic persons have
been largely explained by altered insulin secretion (caused by a
failure in the fusion and release of the insulin-containing granules
in the pancreatic beta cells) [35]. We previously showed that this
beta-cell dysfunction is also present in MetS patients, affecting the
dynamic markers of glucose metabolism [17]. However, the
TCF7L2 pathway has also been involved in several other
biological processes, like the differentiation of adipocytes and the
regulation of adipokines, among others [16,33], and the presence
of the minor allele of rs7903146 gene variation has been linked to
other diseases apart from diabetes, such as the incidence of cancer
[36], or the severity of coronary disease [37].
Despite the fact that lipid metabolism may be a link between
TCF7L2, adipocyte metabolism and coronary disease, few studies
have evaluated fasting lipids, and the influence of gene variations
on this gene and on postprandial lipids remains an unexplored
field. A single previous report found that rs7903146 was linked to
altered postprandial lipid metabolism only in the presence of a
high PUFA intake in a sample of Caucasian origin with subjects
ranging from 17 to 92 years old mostly recruited from a 3-
generational pedigree database [18]. The authors identified beta-
cell dysfunction as the main underlying cause, although the
significance for differences in the HOMA-B index in the full
cohort was nominal (p = 0.041). To further understand the
significance of rs7903146 in human metabolism, we evaluated its
effects in three different settings: healthy young men, middle-aged
persons with MetS and healthy elderly persons, with the last two
cohorts being examined after different dietary models.
Table 1. Baseline characteristics of the participants in the three studies depending on the TCF7L2 rs7903146 SNP.
Young men Elderly persons Metabolic Syndrome
CC (n=34) CT (n=39) TT (n =15) p CC (n=10) CT/TT (n =10) p CC (n=55) CT/TT (n=55) p
Age (years) 22.760.7 2260.3 21.660.7 0.378 67.561.6 68.461.7 0.419 54.260.9 55.660.9 0.261
BMI (kg/m2) 25.360.6 25.960.7 24.861 0.594 33.162.2 30.161.4 0.26 34.560.4 34.760.4 0.75
Weight (kg) 78.161.9 78.462.1 74.362.3 0.463 88.865.7 77.664.8 0.15 93.961.6 91.561.4 0.264
Height (cm) 175.760.9 173.961.2 173.361.4 0.329 163.962.6 159.462.6 0.244 170.160.9 1.6463.0 0.128
Chol (mg/dl) 154.663 156.564.5 145.765.8 0.059 185.868.7 216.867.1 0.013** 21165.2 207.664.7 0.458
TG (mg/dl) 82.267.3 82.365.8 72.866.1 0.635 87.2611.6 117.967.7 0.043** 151.667.7 151.4610.9 0.984
HDL (mg/dl) 47.661.9 47.561.8 4361.4 0.073 55.763.5 52.364.4 0.56 44.761.5 4461.4 0.725
LDL (mg/dl) 90.663.1 92.564.4 81.264.9 0.228 10967.8 137.568.6 0.024** 142.964.5 139.264.1 0.452
Apo A1 (mg/dl) 10663.8 11163.2 99.862.6 0.056 157.369.1 15468.4 0.795 140.362.9 138.363.2 0.653
Apo B (mg/dl) 67.662.9 68.163 66.364 0.934 78.865.8 102.665.8 0.009** 99.162.7 97.162.6 0.463
Chol: total cholesterol. All values are means 6S.E.
*p,0,05 TT vs CT/CC;
**p,0.05 CC vs CT/TT. Adjusted by age and BMI (all cohorts), diet and gender (Metabolic syndrome and aged cohorts), and center of origin (Metabolic Syndrome).
doi:10.1371/journal.pone.0043390.t001
Table 2. AUC of the different lipid particles in the young male
cohort (min*mg/dL)/103.
Young male
cohort Rs7903146 P
Lipemia
(11 hours) CC (n =34) CT (n=39) TT (n=15)
Total TG 89.067.1 90.266.9 86.9610.6 0.967
CHOL 98.562.5 102.562.4 91.563.7 0.053
large-TRL TG 34.863.5 35.063.3 36.565.3 0.966
small-TRL TG 30.661.7 31.862.3 29.761.4 0.964
large-TRL CHOL 5.360.3 5.660.3 5.260.5 0.786
small-TRL CHOL 7.360.7 7.660.6 7.161.0 0.915
APOA1 67.9±1.8 70.8±1.8 60.9±2.7** 0.011
Apo B 41.561.6 44.261.6 44.362.4 0.452
HDL 30.54±1.1 30.0±1.6 25.3±1.6* 0.028
*p,0.05 TT vs CT and TT vs CC.
**p,0.05 TT vs CT. All values are mean6S.E. Adjusted by age and BMI.
doi:10.1371/journal.pone.0043390.t002
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The objective in choosing the first cohort (healthy young men)
was to observe the possible effects of this SNP on a healthy
background, where alterations in the carbohydrate metabolism
were not present and the functional status of the pancreas was, in
theory, optimal. In this setting, we found that the carrier status of a
single minor allele for TCF7L2 rs7903146 was not related to
altered postprandial response, requiring the existence of two
altered alleles (homozygote for the rare alleles) to produce altered
postprandial lipids, consisting of lower HDL and Apo A1 levels
during the postprandial test, which would account for the
diminished donor capacity of Apo CIII, an important feature of
HDL during the postprandial state.
The second cohort model (MetS) was chosen on the basis of our
previous research and published data into the influence of
TCF7L2 on glucose metabolism and beta-cell function [17]. In
our sample, we could find no influence of these gene variations on
postprandial lipemia in this population. What at first sight seemed
a disappointing result may be put down to the fact that TCF7L2
SNPs do not exert the observed effects in the presence of MetS.
Nevertheless, data from a previous comparison of the three
Figure 1. Plasma concentration of adiponectin (Panel A), leptin
(Panel B) and resistin (Panel C) depending on the rs7903146
genotype. *p,0.05 CC vs CT/TT.
doi:10.1371/journal.pone.0043390.g001
Table 3. AUC of the different lipid particles in the metabolic
syndrome cohort under the dominant model assumption
(min*mg/dL)/103.
Metabolic syndrome cohort Rs7903146 P
Lipemia (8 hours) CC (n =55) CT/TT (n =55)
Total TG 97.267.3 104.466.8 0.483
CHOL 94.362.4 96.062.3 0.624
large-TRL TG 38.262.3 40.962.3 0.785
small-TRL TG 25.461.4 27.261.2 0.593
large-TRL CHOL 5.160.3 5.460.3 0.528
small-TRL CHOL 6.960.4 7.060.4 0.491
APOA1 66.061.3 64.361.4 0.387
Apo B 44.161.3 44.661.2 0.816
HDL 19.660.7 19.360.6 0.993
LDL 63.462.0 63.861.9 0.893
large-TRL Apo B 0.9160.08 0.9760.08 0.555
small-TRL Apo B 1.2760.01 1.3060.01 0.872
All values are mean 6S.E. Adjusted by diet, age, gender, BMI and center of
origin.
doi:10.1371/journal.pone.0043390.t003
Table 4. AUC of the different lipid particles in the elderly
persons cohort under the dominant model assumption
(min*mg/dL)/103.
Elderly persons
cohort Rs7903146 P
Short lipemia
(4 hours) CC (n =10) CT/TT (n =10)
Total TG 34.263.8 41.963.8 0.183
CHOL 42.0±1.6 47.8±1.6 0.028*
large-TRL TG 12.962.5 16.762.5 0.305
small-TRL TG 4.6±0.5 6.5±0.5 0.018*
large-TRL CHOL 1.460.1 1.660.1 0.544
small-TRL CHOL 1.4±0.1 2.0±0.1 0.015*
APOA1 35.061.6 36.461.6 0.569
Apo B 18.4±1.2 21.8±1.2 0.042*
HDL 12.260.7 12.160.7 0.940
LDL 23.361.5 26.661.5 0.150
large-TRL Apo B 0.4760.06 0.5560.06 0.351
small-TRL Apo B 0.43±0.06 0.72±0.06 0.004*
*p,0.05 CC vs CT/TT. All values are mean 6S.E. Adjusted by diet, age, gender
and BMI.
doi:10.1371/journal.pone.0043390.t004
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cohorts resulted in the notion that, once homogenized, these MetS
patients showed altered postprandial lipemia, when compared not
only to young men, but also to healthy elderly persons
(unpublished data, J D-L). In this context, it is possible that the
deleterious effects of rs7903146 were not evident in the MetS
cohort because all the participants, even those who did not carry
the ‘‘harmful’’ allele, may have disrupted postprandial lipemia via
other physiopathological pathways.
Our final test model was a cohort of healthy elderly persons. In
this cohort, the carriers of the rare allele of rs7903146 showed
altered postprandial lipemia, with higher total cholesterol and Apo
B, and a higher content of cholesterol, triglycerides and Apo B in
small-TRL particles, accounting for a disrupted clearance of
postprandial particles - which may be related to the greater
severity of cardiovascular events reported for the carriers of
rs7903146 [37]. We also noted higher fasting total cholesterol,
total triglycerides, and high LDL concentration and Apo B
molecules in this last cohort. All these features are pro-atherogenic,
and may have partly determined the altered postprandial lipemia.
We did not find any influence of the type of diet on the results.
When looking for potential underlying mechanisms, we studied
two well-known biological properties of TCF7L2 - its influence in
beta-cell function, and in the adipocyte differentiation - by
measuring the main adipokines present in mature adipocytes
(adiponectin, leptin and resistin). Although it was non-significant in
the case of the young men, both the elderly and the young men
who are carriers of the minor alleles shared an increase in resistin
levels, a hormone which has been related to obesity, or an increase
in insulin resistance [38–39]. As regards adiponectin, the T allele
was related to a lower concentration in the young men’s cohort.
Adiponectin participates in lipid clearance and glucose metabolism
(decreasing gluconeogenesis and increasing glucose uptake) [40],
and is inversely correlated to the harmful features of the
postprandial state [41]. The fact that the young men with the T
allele showed higher adiponectin levels, while the elderly persons
did not, may partially explain the features observed in lipid
clearance in the latter (and absent in the young men), which
implies that young men could somehow boost their lipid clearance
by increasing their adiponectin levels. Moreover, we found higher
levels of leptin (an adipokine that increases in response to obesity,
Figure 2. Area under curve (AUC) of Total Cholesterol and Apo B (Panel A), and Small-TRL contained Cholesterol, TG and Apo B
(Panel B) depending on the rs7903146 in aged cohort (mean 6S.E). *p,0.05 TT vs TC/TT. Values are in (min*mg/dL)/103.
doi:10.1371/journal.pone.0043390.g002
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inhibiting appetite at brain level [42]) in the elderly persons who
were homozygote for the common allele, which may be related to
the higher BMI found in these persons in our sample.
Beta-cell dysfunction has been identified as the main cause by
which TCF7L2 variants may exert their effects on glucose
metabolism [31,35], and rs7903146 may impair the ability of
hyperglycemia to suppress glucagon [43]. In our study, HOMA-B
measures did not differ in any case between carriers and non-
carriers of the minor alleles of the SNPs, in the two populations in
which the SNPs influenced the postprandial lipids, which may
suggest that, despite the well-established effects of rs7903146 on
beta-cell function, there could be additional pathways underlying
the effects of rs7903146 on postprandial lipids. At this point, a
combination of the direct effects of rs7903146 on insulin secretion
with those derived from the crosstalk with other regulators of the
energy metabolism via adipokines cannot be discarded, and is
something that, in our opinion, may be looked into further in
in vitro studies.
We must be cautious therefore when extrapolating our results,
because our study presents some limitations. The possibility of
epistasis should be considered between the rs7903146 SNP and
postprandial lipemia response in terms of possible linkage
disequilibrium in the vicinity of other related genes. On the other
hand, oral fat loads have still not been satisfactorily categorized, as
this has mainly been studied with different oral fat loads and
different timing of blood sampling. In this study, we used different
methodology in order to explore the determinants and the
pathophysiological aspects of exaggerated/delayed postprandial
lipemia in humans. This limitation regarding the different
experimental designs is a factor to be considered.
Another point to be taken into account is that, while the effects
of rs7903146 in our study are circumscribed to the postprandial
measurements in the young men, they are also evident in the
fasting state in the aged cohort, and, hence, it may be possible that
some of the effects found in this latter cohort are due to the fasting
figures. Nevertheless, the postprandial lipid metabolism involves
many important clearance pathways and actors, such as the
lipoprotein lipase or the different apolipoproteins that could limit
the extent of the fasting effects in the postprandial state. In that
context, our work shows how the modifications exerted by
rs7903146 in the fasting state also extend to the fed state.
To sum up, we have shown how the gene variation rs7903146
negatively influences lipid metabolism during postprandial lipemia
in healthy subjects (young men and elderly persons), while we did
not find any effects in MetS persons. The elderly persons also
exhibited altered fasting lipids.
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